COMMUNIQUÉS West-GlobeNewswire

D5 Health - Personalized Longevity Clinic Opens Its Doors in Raleigh, NC
03/11/2025
Innovative Clinic Offers Personalized Health Solutions to Optimize Vitality and Longevity Raleigh, NC, Nov. 03, 2025 (GLOBE NEWSWIRE) -- D5 Health , a personalized longevity clinic in Raleigh, is thrilled to announce [...]
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
03/11/2025
WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today issued a statement to provide clarity regarding its accumulated deficit reported under U.S. GAAP [...]
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
03/11/2025
ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy ® (epinephrine nasal spray) Oral presentation to report results from real world data on the [...]
Organogenesis Applauds CMS’s Significant Step In Payment Reform
03/11/2025
With evidence-based portfolio including technologies in each FDA category, we believe we are best positioned in the skin substitutes market for 2026 and beyond CANTON, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
03/11/2025
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 3 novembre 2025 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement [...]
Rendever Receives Nearly $4.5 Million in NIH Funding to Overcome Social Isolation for Older Adults while Supporting Caregivers
03/11/2025
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Rendever , the company leading the industry in immersive technology for aging, has secured nearly $4.5 million in grant funding from the National Institutes of Health (NIH) to [...]
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting
03/11/2025
Two oral and seven poster presentations further support the CARVYKTI ® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session SOMERSET, N.J., [...]
NeuroSigma Announces New Publication Showing Real-Time Effects of External Trigeminal Nerve Stimulation (eTNS) on Brain Activity
03/11/2025
Peer-reviewed results of PET neuroimaging demonstrate rapid and profound changes to humans receiving eTNS LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. , a Los Angeles-based bioelectronics company, [...]
Legal Steroids for Bulking, Cutting, Strength from CrazyBulk: Best Selling Legal Steroid Alternatives for Muscle Growth and Bodybuilding in 2025
03/11/2025
Crazy Bulk's Introduces Best Legal Steroid Alternatives Safe and Most Popular Legal Steroids for Muscle Building and Cutting supplements in 2025. It Help to Boost testosterone, and improve muscle growth, strength, and [...]
Zelluna ASA – Contemplates private placement
03/11/2025
Zelluna ASA – Contemplates private placement of NOK 50-55 million and retail offering to advance into first-in-human trial of its “off-the-shelf” TCR-NK therapy NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR [...]
Zelluna ASA Reports Third Quarter 2025 Financial Results and Provides General Business Update
03/11/2025
Oslo, Norway, 3 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its third quarter 2025 [...]
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel
03/11/2025
–Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development– SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE [...]
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
03/11/2025
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust safety profile with no dose limiting toxicities (DLTs [...]
Cellectis to Present a Development Update for eti-cel at ASH 2025
03/11/2025
Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHL Preclinical data demonstrated that combining eti-cel with low- [...]
Cellectis présentera de nouvelles avancées sur éti-cel lors du congrès annuel de l’ASH 2025
03/11/2025
Les données préliminaires récemment présentées pour eti-cel (UCART20x22) montrent un taux de réponse global (ORR) de 86 % et un taux de réponse complète (CR) de 57 % (n=7), soulignant le potentiel de cette approche pour [...]
MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule
03/11/2025
Company is Well Positioned to Continue to Compete and Grow MARIETTA, Ga., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and [...]
Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting
03/11/2025
– Data to be featured in two oral presentations on December 8, 2025 – – Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate use – SAN DIEGO and TOKYO, [...]
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
03/11/2025
CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status ~30% CRc rate observed at clinically [...]
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
03/11/2025
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in- [...]

Pages